CCL22

CCL22

CCL22 Molekülinformation

Molecule Name
ATP Binding Cassette Subfamily D Member 1
Molekülalias
MDC,ABCD-1,SCYA22,STCP-1,DC,B-CK,A-152E5.1
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
ATP Binding Cassette Subfamily D Member 1,Adrenoleukodystrophy Protein,ATP-Binding Cassette Sub-Family D Member 1,ALDP,ATP-Binding Cassette, Sub-Family D (ALD), Member 1,ABC42,ABCD1,AMN,ALD,ATP Binding Cassette Transporter, Subfamily D, Member 1,Adrenoleukodystrophy
Molekülhintergrund
This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes. The product of this gene binds to chemokine receptor CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.

CCL22 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Pozetaldogene ormesparvovecSBT-101Phase 2 ClinicalSwanBio Therapeutics Ltd
Adrenoleukodystrophy
Details
TYF-ABCD1TYF-ABCD1ClinicalShenzhen Geno-Immune Medical Institute
Adrenoleukodystrophy
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Elivaldogene autotemcelApprovedGenetix Biotherapeutics Inc, InsermLenti-D, SkysonaUnited StatesAdrenoleukodystrophyGenetix Biotherapeutics Inc2021-07-27
Adrenoleukodystrophy
Details